ASLAN Pharmaceuticals Limited (ASLN) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
Address
83 Clemenceau Avenue
Singapore, 239920
Singapore
Phone
65 6222 4235
Website
Sector
Healthcare
Industry
Biotechnology
Employees
35
First IPO Date
May 04, 2018
| Name | Title | Pay | Year Born |
| Carl Alan Jason Morton Firth | Founder, Chief Executive Officer & Executive Director | 0 | 1973 |
| Chi-Chin Wang | IR & Corporate Development Director | 0 | N/A |
| Alexandre Kaoukhov | Chief Medical Officer | 0 | 1974 |
| Ben Goodger | General Counsel | 0 | 1963 |
| Kiran Kumar Asarpota | Chief Operating Officer & Head of Finance | 0 | 1979 |
| Stephen Doyle | Chief Business Officer | 0 | 1973 |
| Charlie Hsu | Investor Relations Director | 0 | N/A |
ASLAN Pharmaceuticals Limited is a biopharmaceutical firm operating at the clinical stage, primarily focused on immunology, and dedicated to creating innovative treatments that profoundly enhance patients' lives. Its advanced therapeutic pipeline features ASLAN004, a monoclonal antibody currently being evaluated for atopic dermatitis and a range of other immunological disorders. Also under development is ASLAN003, a small-molecule inhibitor of dihydroorotate dehydrogenase, intended to treat autoimmune conditions. The company is involved in a joint venture with JAGUAHR Therapeutics Pte. Ltd. and Bukwang Pharmaceutical Co., Ltd., aimed at pioneering immuno-oncology therapeutics that target the AhR pathway. Furthermore, ASLAN maintains partnerships with various entities, including Almirall, Array BioPharma, and CSL Limited. Established in 2010, the company's headquarters are located in Singapore.